Physician profile
Spencer Li
NPI 1467433011
$2,638.02
in general payments reported to CMS, 2019-2025
19 companies · $589 in 2025
The $589 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $179 · 2021: $58.19 · 2022: $437 · 2023: $261 · 2024: $263 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.56 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $366.61 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.78 | 2019-2025 | Trulance, Xifaxan |
| Pfizer INC. | $272.76 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $207.72 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $192.65 | 2019-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $165.89 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $83.01 | 2019-2024 | Sutab, Suflave |
| Allergan, INC. | $82.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $81.05 | 2019-2022 | |
| Ardelyx, INC. | $68.28 | 2022-2023 | Ibsrela |
| Madrigal Pharmaceuticals | $51.27 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $37.85 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $35.02 | 2019-2020 | |
| Alfasigma USA, INC. | $30.78 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $28.87 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $19.95 | 2025 | Vowst |
| Sandoz INC. | $19.89 | 2023 | Hyrimoz |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.